

develops and conducts studies, including economic and behavioral studies, to evaluate the effectiveness of interventions and programs to prevent viral hepatitis and to identify barriers to prevention services such as immunization, counseling, testing, medical referral, and management; (6) develops and evaluates health services models for prevention of infection with hepatitis viruses and associated liver disease; (7) provides leadership and coordinates the development of national standards and performance objectives for prevention of viral hepatitis and liver disease and works with agencies and partners to adopt these standards; (8) develops indicators and measures by which to evaluate the performance and effectiveness of viral hepatitis prevention programs; (9) disseminates information through scientific publications and presentations; and (10) provides training opportunities for Epidemic Intelligence Service Officers and others in CDC sponsored programs, postgraduate students, post-doctoral fellows, and other public health scientists.

*Laboratory Branch (HCR44).* (1) Conducts research and applies state-of-the-art laboratory methods in support of studies related to the epidemiology, molecular epidemiology, and natural history of acute and chronic infections with hepatitis viruses and liver disease; (2) conducts research to develop and validate diagnostic approaches to identify infections with hepatitis viruses; (3) develops and evaluates methods to prevent acute and chronic infection and disease outcomes, including vaccines; (4) determines the viral, immunologic, and other host responses to infection with hepatitis viruses in humans and animal models; (5) identifies and characterizes agents that cause hepatitis; (6) provides reference diagnostic testing for markers of infection with hepatitis viruses for state and local public health laboratories; (7) provides the leadership and collaboration to ensure the transfer to public health laboratories, both nationally and internationally, state-of-the-art methods and approaches for the identification and diagnosis of infections with hepatitis viruses; (8) develops and maintains archives of clinical specimens from clinical trials and epidemiologic and laboratory studies; (9) disseminates information through scientific publications and presentations; and (10) provides training opportunities for persons in CDC sponsored programs, postgraduate students, post-doctoral fellows, and other public health scientists.

Dated: April 14, 2002.

**David W. Fleming,**

*Acting Director, CDC.*

[FR Doc. 02-9248 Filed 4-16-02; 8:45 am]

**BILLING CODE 4160-18-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 01E-0363]

#### Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX; Extension of Comment Period

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; extension of comment period.

**SUMMARY:** The Food and Drug Administration (FDA) is extending to April 26, 2002, the comment period for the regulatory review period determination for MIFEPREX, published in the **Federal Register** of January 25, 2002 (67 FR 3724). The agency is taking this action in response to a request for an extension.

**DATES:** Submit written or electronic comments on the regulatory review period determination for MIFEPREX by April 26, 2002.

**ADDRESSES:** Submit written comments and petitions to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>.

**FOR FURTHER INFORMATION CONTACT:** Claudia V. Grillo, Office of Regulatory Policy (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of January 25, 2002 (67 FR 3724), FDA published a document entitled "Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX." The document set forth the determination of the regulatory review period for purposes of patent term extension for the human drug product MIFEPREX. The document announced that FDA determined that the applicable regulatory review period for MIFEPREX was 2,249 days, and that of this time, 593 days had occurred during the testing phase of the regulatory review period, while 1,656 days had occurred during the approval phase. The notice explained how these periods of time were derived.

FDA received a letter dated March 22, 2002, from an attorney representing the Population Council (the patent holder) and others, requesting that the agency extend the comment period on the regulatory review period for 30 days, until April 26, 2002, explaining that additional time was needed to reach a licensing agreement. FDA has determined that it is appropriate to grant this request.

Interested persons may submit to the Dockets Management Branch (see **ADDRESSES**) written or electronic comments on the regulatory review period determination for MIFEPREX on or before April 26, 2002. Three copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 27, 2002.

**Jane A. Axelrad,**

*Associate Director for Policy, Center for Drug Evaluation and Research.*

[FR Doc. 02-9364 Filed 4-16-02; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4734-N-14]

#### Notice of Submission of Proposed Information Collection to OMB; Small Cities Program Performance Assessment Report

**AGENCY:** Office of the Chief Information Officer, HUD.

**ACTION:** Notice.

**SUMMARY:** The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

**DATES:** *Comments Due Date:* May 17, 2002.

**ADDRESSES:** Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2506-0020) and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503; Fax number

202-395-96974; E-mail *Joseph\_F.\_LackeyJr@OMB.EOP.GOV*.

**FOR FURTHER INFORMATION CONTACT:** Wayne Eddins, Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street, Southwest, Washington, DC 20410; e-mail *Wayne\_Eddins@HUD.gov*; telephone (202) 708-2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.

**SUPPLEMENTARY INFORMATION:** The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. chapter 35). The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the

information and its proposed use; (5) the agency form number, if applicable; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the name and telephone number of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.

This Notice also lists the following information:

- Title of Proposal:* Small Cities Program Performance Assessment Report.
- OMB Approval Number:* 2506-0020.
- Form Numbers:* HUD-4052.
- Description of the Need for the Information and its Proposed Use:* The

information collected from grant recipients participating in the state-administered CDBG program provides HUD with financial and physical development status of each activity funded. These reports are used to determine grant recipient performance and for HUD's Annual Report to Congress on accomplishments. The Housing and Community Development Act of 1974, as amended, requires grant recipients that receive CDBG funding to submit a Performance Assessment information Report (PAR) on an annual basis to report on program progress; and such records as may be necessary to facilitate review and audit by HUD of the state's administration of CDBG funds (section 104(e)(2)).

*Respondents:* Business or other for-profit entities—Grant recipients participating in the State-administered CDBG program.

*Frequency of Submission:* Annually.

	Number of respondents	Annual responses	×	Hours per response	=	Burden hours
Reporting burden .....	800	1		8		64,00.

*Total Estimated Burden Hours:* 64,000.

*Status:* Reinstatement, with minor changes, of a previously approved collection for which approval expired in January 2000.

**Authority:** Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.

Dated: April 9, 2002.

**Wayne Eddins,**

*Departmental Reports Management Officer, Office of the Chief Information Officer.*

[FR Doc. 02-9258 Filed 4-16-02; 8:45 am]

**BILLING CODE 4210-72-M**

**DEPARTMENT OF THE INTERIOR**

**Minerals Management Service**

**Historical Royalty and Production Data**

**AGENCY:** Minerals Management Service (MMS), Interior.

**ACTION:** Notice of availability.

**SUMMARY:** MMS implemented a new financial management system on November 1, 2001. As part of the implementation process, royalty and production data reported to our predecessor system was transferred to the new system. Reporters will need this information to make accurate adjustments and corrections to

previously reported data. This notice informs reporters where and how they may obtain their historical royalty and production data.

**DATES:** This information is available April 17, 2002.

**ADDRESSES:** To request access to historical data via the Internet, send a completed System Access Request Form (SARF) to Minerals Management Service, Attention: Information Technology Center, Policy and Security Group, P.O. Box 25165, Mail Stop 340G4, Denver, CO 80225. To request historical data on a compact disk, send a written request to Minerals Management Service, Reporting Services, Attention: Kathy Ciferri, P.O. Box 5760, Mail Stop 357B1, Denver, CO 80217-5760.

**FOR FURTHER INFORMATION CONTACT:** Ms. Kathy Ciferri, Minerals Management Service, P.O. Box 5760, MS-357B1, Denver, CO 80217-5760; telephone number (303) 231-3060; fax number (303) 231-3608; e-mail *kathleen.ciferri@mms.gov*.

**SUPPLEMENTARY INFORMATION:** Before the new financial management system was implemented November 1, 2001, royalty data reported to MMS on Federal and Indian mineral leases was entered into the Auditing and Financial System (AFS). Production data reported to MMS on Federal and Indian mineral leases

was entered into the Production Accounting and Auditing System (PAAS).

As part of the implementation of the new financial management system, MMS converted all royalty data received between January 1, 1983, and October 16, 2001, to the new Report of Sales and Royalty Remittance (Form MMS-2014, revised October 1, 2001) format. MMS converted all production data reported on the Monthly Report of Operations (Form MMS-3160), the Oil and Gas Operations Report (OGOR), and the Production Allocation Schedule Report (PASR) received between January 1, 1983, and October 16, 2001, to the new OGOR and PASR (Forms MMS-4054 and MMS-4058, revised October 1, 2001) formats. This historical royalty and production data is stored in the new financial management system in the revised formats.

This historical data is available to the original reporters of the data. MMS is fully aware of the necessity to protect proprietary data; consequently, data will not be released to anyone, other than the original reporter, unless the requester demonstrates a legal right to that data. MMS will provide historical data by reporter code to companies who merge when complete ownership can be legally demonstrated. Companies that acquire only a portion of another company's leases will not receive